-
Views
-
Cite
Cite
Mohammed Abd El Fattah El Malatawy, Mohamed Mohamed Bahaa El Din, Eslam Safwat Mohamed, Heba Ahmed Faheem, Shadi Emad Shawkey Isac, Recurrence of Hepatocellular Carcinoma after Living Donor Liver Transplantation Prevalence, Patterns, Perioperative Factors and Outcome, QJM: An International Journal of Medicine, Volume 117, Issue Supplement_1, June 2024, hcae070.284, https://doi.org/10.1093/qjmed/hcae070.284
- Share Icon Share
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third cause of cancer-related mortality world- wide. The incidence of HCC is on the increase, and it is a major threat to our modern life. Epidemiological studies have indicated that HCC are related to chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection.
To detect prevalence, patterns, perioperative factors and outcome of recurrence of HCC after living donor liver transplantation.
This was a cross sectional study based on the review of medical records of all patients undergoing LT at Ain Shams Centre of Transplantation, between January 1, 2010, and December 31, 2018.
we detected prevalence, patterns, perioperative factors and outcome of recurrence of HCC after living donor liver transplantation.
Oral lactoferrin could not be used as a substitute to totally replace IV ferrous sulphate in treating iron deficiency anemia in end stage renal disease (ESRD) on dialysis. Oral lactoferrin could not even control Hb level constant without dropping in patients with end stage renal disease (ESRD). Oral lactoferrin had some gastrointestinal effects on some patients which did not allow compliance on the medication.
- hemodialysis
- medical records
- kidney failure, chronic
- cancer
- hepatitis c, chronic
- iron deficiency anemia
- carcinoma, hepatocellular
- epidemiologic studies
- hepatitis b, chronic
- lactoferrin
- liver transplantation
- living donors
- perioperative care
- infections
- hepatitis b virus
- hepatitis b virus measurement
- mortality
- transplantation
- viruses
- hepatitis c virus
- ferrous sulfate